Science

Unmet Need & Differentiation: Apogee concentrates on targets that address significant unmet medical needs. Apogee prioritizes programs with the potential to be first‑in‑class or best‑in‑class, delivering transformative benefits where current treatments are inadequate, for example, novel mechanisms in endometriosis and adenomyosis.

Genetic & Biological Evidence: Apogee prioritizes targets backed by compelling human biology, including genetic associations, disease‑relevant pathways, and clinical observations that implicate a pathway in disease. Targets with validated links, such as gene variants or differential expression that contribute to pathology, raise confidence that modulation will have meaningful impact.

Tissue-Specific Expression & Biomarkers: Apogee favors targets selectively expressed in disease‑relevant tissues or cell types, helping ensure on‑target activity and reduced off‑tissue effects. Apogee also evaluates the availability of biomarkers to track target engagement and disease activity so that preclinical and clinical outcomes can be measured precisely.

Translational Validation: Apogee places a strong emphasis on translational science. Apogee requires compelling evidence that modulating a target yields therapeutic benefit in predictive systems, such as disease animal models or patient‑derived cell models. Apogee designs experiments to mirror clinical scenarios as closely as possible, maintaining clear line of sight from bench to bedside.

Modality Flexibility – Small Molecules & Biologics: Our discovery approach is modality‑agnostic. Apogee selects the modality best suited to each target, spanning small molecules, peptides, biologics, and antibody–drug conjugates (ADCs), to optimize efficacy, safety, and delivery.